Program: IgY-112 Stage: Discovery IgY for Celiac disease contain polyclonal IgY antibodies that block the interaction of hypersensitive or excessive mucosal immune responses with microbial and protein components that are associated with celiac disease pathogenesis. We are researching the effectiveness of an oral therapeutic using a capsule-based format to deliver the antibodies directly [...]
Program: IGY-110 Stage: Preclinical IGY-110 is an IgY polyclonal antibody targeting the spike proteins of the coronavirus directly via intranasal delivery to the key site of coronavirus entry and infection. Enteric-coated capsules will also be used to help reduce virus activity in the gastrointestinal tract. The intranasal delivery approach is supported by a recent [...]
Program: IgY-102 Stage: Discovery Universal influenza IgY nasal spray contains polyclonal antibodies IgY that neutralize a broad spectrum of influenza virus strains including those that cause potential pandemics. The concept is based on the study published in PloS ONE, DOI: 10.1371/journal.pone.0010152 Please contact us to learn more about IGY-102 or to explore partnership [...]
